Vera Therapeutics, Inc. (NASDAQ: VERA) is a Healthcare company (Biotechnology) with a market capitalization of $1.9B. The Maz Rating grades it against the other companies in its sector.
Vera Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $26.20, Vera Therapeutics, Inc. trades at 183.7x sales and 5.7x book value. Over the last twelve months it generated about $10M of revenue and a net loss of $428M. It runs a gross margin of 67.9%, an operating margin of -4160.1% and a net margin of -4041.2%. It shows return on equity of -90.0%, return on invested capital of -104.3% and a free cash flow yield of -19.9%. On the balance sheet: a debt-to-equity ratio of 0.23 and a current ratio of 7.91. Over the past 52 weeks the share price ranged from $25.82 to $56.05, with a beta of 0.95.
Vera Therapeutics, Inc. does not currently pay a dividend.
14 Wall Street analyst ratings cover the stock: 1 Strong Buy, 12 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Vera Therapeutics, Inc. (VERA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 3.33% / 30% · (Cash+Inv) / Mkt Cap (36m) 16.9% / 30% · Interest income / Revenue 42.2% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 3.33% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 16.9% / 33% · Receivables / Mkt Cap (36m) 0.64% / 49% · Interest income / Revenue 42.2% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 3.33% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 16.9% / 33.33% · Receivables / Mkt Cap (24m) 0.64% / 33.33% · Interest income / Revenue 42.2% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 12.8% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 93.2% / 33.33% · Receivables / Avg Assets (4Q) 0.92% / 33.33% · Interest income / Revenue 42.2% / 5% | Fail |
| FTSE | Debt / Total Assets 16.2% / 33.33% · (Cash+ST Inv) / Total Assets 82.5% / 33.33% · (Cash+Recv) / Total Assets 85.6% / 33.33% · Interest income / Revenue 42.2% / 5% | Fail |
No. As of September 2026, Vera Therapeutics, Inc. (VERA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Vera Therapeutics, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 42.2% of each dividend: Vera Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.